There are several limited approaches to treat epilepsy in hospitals, for example, using medicines, surgery, electrical stimulation and dietary interventions. Despite the availability of all these new and old approaches, seizure is particularly difficult to manage. The quest for new antiepileptic molecules with more specificity and less CNS toxicity continues for medicinal chemists until a new and ideal drug arrives. This review covers new antiseizure molecules of different chemical classes, the exact mode of action of which is still unidentified. Newer agents include sulfonamides, thiadiazoles, semi-and thiosemicarbazones, pyrrolidine-2,5-diones, imidazoles, benzothiazoles and amino acid deriva tives. These new chemical entities can be useful for the design and development of forthcoming antiseizure agents.
INTRODUCTION
Epilepsy is a collective term for a group of chronic CNS disorders. All kinds of epilepsies display the occurrence of unprovoked, excessive, sudden, self-regulated neuronal discharge that results in a seizure. Because of excessive neuronal discharge, the finely organized pattern of the integrative activity of the brain is abolished (1) .
Prevalence of the disease is observed in every corner of the world, with underdeve loped countries being more vulnerable. It is estimated that almost 50 million people around the world are affected by epilepsy (2) . Older people are more prone to epileptic spell (3) . The exact etiology of the disease is still unknown. However, factors associated with epilepsy include brain trauma, strokes, brain cancer and drug and alcohol misuse, among others. The multifactorial origin of the disease produces a high degree of disablement to successful discovery of antiepileptic drugs (4) . In many cases, there is no direct family relation to the epileptic condition at all. However, some researchers have confirmed that some special types of epilepsy take place more often in some families. It was recently revealed that such types of epilepsy were connected with the transfer of specific genes from one generation to another (5-10). There are many mutated genes responsible for various types of inheritable epilepsies, for example, familial nocturnal frontal lobe epilepsy is caused by inheritance of mutated CHRNA2, CHRNA4 and CHRNB2 genes. In the same way, febrile seizures, generalized epilepsy with febrile seizures plus and Dravet syndrome are caused by inheritance of mutated SCN1A, SCN2A, SCN2B and GABRG2 genes. Many studies have confirmed that epigenetically facilitated regulation of Na + channel genes (SCN1A, SCN1B, SCN2A and SCN3A) associated with generalized epilepsy with febrile seizures plus (GEFS+) are mediated via DNA methylation and methyl-CpG-binding domain 2 (MBD2) binding (11) . Some antiepileptic drugs produce epigenetic changes. For example, valproate induces defects of epigenetic transcriptional regulatory mechanisms in glial cells, resulting in reduced cell proliferation, which may in turn lead to cognitive dysfunction or mental illness (12, 13) .
Over the past ten years, a large number of new antiepileptic drugs (AEDs) and nonpharmacologic remedies have been added to treat epilepsy. The new drugs are designed to address specific pathophysiologic defects such as seizure generation or spread where the old medicines are not useful any more. Other novel approaches to control epilepsy include electrical stimulation devices, such as vagus nerve stimulator (14) (15) (16) , deep brain stimulation (DBS) (17, 18) and dietary interventions (ketogenic diet) (19) (20) (21) (22) . Despite the availability of all new and old AEDs, along with the arrival of new techniques, seizures are particularly challenging to treat. The old generation antiepileptic drugs (AEDs) such as phenobarbital, primidone, phenytoin, carbamazepine, ethosuximide and benzodiazepine are potent and extensively used but exhibit considerable adverse effects and also fail to adequately control seizures (23) . On the other hand, new AEDs, for example gabapentin, topiramate, lamotrigine, levetiracetam, vigabatrin, and rufinamide are not as potent as the old AEDs and are used as an add-on therapy. They all exhibit significant CNS-related and other side effects (24) . This study suggests that only a small number of new AEDs adequately manage major types of epilepsy, the remaining drugs control only one or two types. The undesired side effects and failure to control the major types of epilepsy compel the researchers to find candidates that would meet all the requirements for an ideal drug.
The antiseizure drugs, which are currently prescribed in the clinics, are categorized based on their mode of action as follows ( Fig. 1): (i) drugs that block the sodium channel, for example, phenytoin, carbamazepine, oxcarbazepine, etc., (ii) drugs that activate GABA-mediated inhibitory action, such as benzodiazepines, barbiturates, vigabatrin, tiagabine, (iii) drugs that block the Ca 2+ channel, for example, pregabalin, gabapentine, etc., (iv) drugs that inhibit glutamate receptors (both NMDA and AMPA), for example, felbamate, topiramate, etc.
Some drugs possess a combination of actions, often coupled with additional and unknown mechanisms (25, 26) ; these include valproic acid, lamotrigine, zonisamide, etc.
The newly designed and synthesized antiepileptic agents have been surveyed over the last few years. The diversity of chemical structures and various modes of action of anticonvulsant agents make it hard to attain a universal way of discovering new drugs.
Novel antiepileptic molecules are discovered via screening or modification in the structure of already existing drugs but not by a mechanism-based design.
This review highlights new antiseizure agents containing various chemical structures whose exact mode of action is unknown. These newly synthesized analogues comprise sulfonamides, heterocyclic compounds, functionalized amino acids, and others. These chemical classes of compounds can be useful for the design and development of new antiepileptic drugs in the future.
NEW ANTICONVULSANT AGENTS: A STRUCTURE BASED REVIEW

Sulfonamide derivatives
This class of drugs has displayed a large number of clinical uses. Some of these drugs are used as antimicrobials, also called sulpha drugs. Some are carbonic anhydrase (CA) inhibitors, which are used as diuretics and antiepileptic drugs. In search of newer anticonvulsant agents, researchers discovered acetazolamide and methazolamide (Fig. 2) . In general, these drugs are 5-membered heterocycles containing a sulfonamide and an amide as well as a 1,3,4-thiadizole nucleus. They exhibit potent carbonic anhydrase inhibitory activity. Topiramate and zonisamide are recently developed antiepileptic drugs bearing different sulfonamide groups in their structure (Fig. 2 ). Scozzafava and Supuran (27) (28) (29) (30) (31) (32) developed several new carbonic anhydrase inhibitors, which are mainly derivatives of sulfonamide. Recent progress in the development of anticonvulsant agents containing sulfonamide moiety is summarized in Table I . 
Derivatives of thiadiazole
Thiadiazoles are five-membered heterocyclic rings bearing two nitrogen atoms and one sulfur with two nitrogen-carbon double bonds (C=N). These conjugated double bonds between atoms provide the thiadiazole ring aromatic property. Four likely structures can be perceived on the basis of the locations of one sulfur and two nitrogen atoms (Fig. 3) . These structures do not interchange and are hence structural isomers (not tautomers). Various isomers of thiadiazole are used as the basic moiety in the process of drug discovery and development (36) (37) (38) . Table II gives an overview of thiadizole-containing new derivatives that display significant antiseizure activity in various animal models.
Semi-and thiosemi-carbazones as anticonvulsant agents
During the last two decades, semicarbazones have been extensively investigated for their anticonvulsant properties (51) (52) (53) (54) . In the conventional screening process, 4-(4-fluorophenoxy) benzaldehyde semicarbazone was discovered as a lead molecule against the electroshock (MES) seizure test. The protective index of this compound is higher than that of carbamazepine, phenytoin and valproate (55) . Later on, a large number of scholars have attempted to find new molecules with significant anticonvulsant activity (Table III) . MES activity at 4 h 2c; R=3-CH and 2-CH highly neurotoxic 3 3 Certain substituents, such as Cl, CH 3 , and NO 3 , in phenyl bound to nitrogen produce highly active analogues in the electroshock seizure test.
Akgul et al.
R =CH 1 3 R=3-OH, 4-Cl, 4-Br
These derivatives demonstrated protection in MES and scPTZ seizure models.
Siddiqui et al.
CNS -central nervous system, MES -maximal electroshock seizure, scPTZ -subcutaneous pentylenetetrazole
Pyrrolidine-2,5-diones as anticonvulsants
Derivatives of pyrrolidine-2,5-dione, as heterocyclic compounds, have been widely applied in medicinal chemistry. They exhibit abundant biological activities, especially in seizure and tyrosinase inhibitory action. Therefore, progress of new and efficient approaches for the preparation of multi-substituted pyrrolidine-2,5-dione derivatives is a burning issue in organic and medicinal chemistry (61) .
Literature survey has revealed that Obniska and Kaminski (62) (63) (64) (65) (66) , along with other researchers, worked extensively on pyrrolidin-2,5-diones as potential anticonvulsant agents. Some recently developed anticonvulsant agents having pyrrolidin-2,5-dione in their structure are presented in Table IV . Derivative 6 was observed to be highly active in MES and scPTZ test models. Compound 15 was observed to be the most protective against both electroshock (MES) and chemoshock (scPTZ). 22c; R = 4-OCH -C H - 3 6 4 Three analogues 22a-c were found to be protective at a dose of 30 mg kg -1 with or without significant neurotoxicity.
Rajak et al. (45)
N
Al Rohaimi (50)
ED 50 -median effective dose, MES -maximal electroshock seizure, PTZ -pentylenetetrazole, scPTZ -subcutaneous pentylenetetrazole In anti-MES and anti-scPTZ tests, compounds 31c and 31d were highly active. In psychomotor seizure 6-Hz test, compounds 31a and 31b were highly active.
Obniska et al. Most anti-MES and anti-scPTZ compounds were 32a-d.
32a and 32c displayed high activity in the 6-Hz psychomotor seizure screening. In the MES seizure test, 38b, 38c and 38e were the most active compounds. In the scPTZ test, 38a and 39 were the most active compounds.
Some compounds were also found active against the psychomotor seizure 6-Hz test, for example, 38d and 40.
Obniska et al. 
42
Broad spectra of activities across the preclinical seizure models were displayed by compounds 41b, 41c and 42.
Besides anticonvulsant properties, compound 41a diminished the pain responses in the formalin model of tonic pain in mice. The most active analogues were 44a having ED 50 
Imidazoles as anticonvulsant agents
Imidazole and its analogues are five-membered heterocyclic structures having two nitrogen atoms separated by one carbon atom. Recent studies have revealed that imidazole analogues have attracted a great deal of attention owing to their broad range of biological activities such as analgesic (80), anti-inflammatory (81), etc. Literature survey has also shown that imidazole-heterocyclic analogues could be an important class of antiseizure agents; an existing antiseizure drug, phenytoin, contains an imidazole ring (82) . Some potent and recently developed imidazole bearing anticonvulsant agents are summarized in Table V . 
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Compound 51 emerged as a highly active candidate showing 100 % protection at a very low dose in the chemoshock (scPTZ) screen without any neuromotor impairment.
Attia et al. (88) CNS -central nervous system, ED 50 -median effective dose, MES -maximal electroshock seizure, scPTZ -subcutaneous pentylenetetrazole, TD 50 -median toxic dose
Benzothiazoles as anticonvulsants
Benzothiazole belongs to the family of bicyclic heterocyclic compounds having the benzene nucleus fused with a five-membered ring comprising nitrogen and sulfur atoms. Benzothiazole is an important scaffold with a wide spectrum of biological activities (89) .
Work on benzothiazoles as anticonvulsant agents started recently and now we have a modest number of articles that validate benzothiazoles as potential candidates for controlling seizures (Table VI) (90) (91) (92) (93) (94) (95) (96) (97) (98) (99) (100) .
Functionalized amino acids (derivatives of amino acids) as anticonvulsants
Kohn and his team (101) revealed a novel class of anticonvulsants which were analogues of amino acids, called functionalized amino acids. Functionalization of the amino and carboxyl terminal of amino acids with different substituents exhibits anticonvulsant activity (102) (103) (104) (105) .
Heterocyclic amino acid derivatives are based on a proline-like structure having a nitrogen-containing ring in which the nitrogen atom of heterocyclic moiety will serve as amino function and carboxylic group will be attached to the ring. Fig. 4 shows some heterocyclic amino acid derivatives that are used as an add-on therapy for the treatment of epilepsy. Compounds 53a-c showed significant activity in MES and scPTZ tests with no sign of neurotoxicity.
Rana et al. (91) Both analogues 56a,b showed significant activity in MES and scPTZ tests after 0.5 h of administration, with less or equivalent toxicity compared to carbamazepine.
Siddiqui et al. 
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Compound 59 was found to be the most active in the MES seizure test with ED 50 value of 13.6 mg kg 
66
The ED 50 Tiagabine, a heterocyclic amino acid analogue with nipecotic acid function, is used as a prescription medicine for the treatment of partial seizures (106) . A fair number of newly synthesized amino acid derivatives as potential anticonvulsant agents are summarized in Table VII .
CONCLUSIONS
The present review provides an insight into new chemical entities that have shown promising antiepileptic activity and updates the knowledge of currently available AEDs.
Many of the agents shown in this review have been screened by the antiepileptic drug development program. Their antiseizure activity has been assessed through in vivo screen-ings, although the exact mode of action of many agents is still unidentified. Some of the newer anticonvulsant analogues are prepared via structural changes of pre-existing drugs, whereas others have been developed with the specific objective of altering targets. Such new synthetic agents generally come from different chemical groups. Some of them represent compounds containing five-or six-membered or other heterocyclic rings in their structure. However, a significant number of literature reports suggest that analogues of amino acids can act as valuable antiseizure agents. Discovery of a large number of active leads may also help in finding alternative drug candidates in the event of drug tolerance. Compounds mentioned in this review can be used in the future as potential drug candidates with more efficacy and lesser toxicity.
Abbreviations, acronyms, symbols. -AEDs -antiepileptic drugs; AMPA -α-amino-3-hydroxy-5--methyl-4-isoxazolepropionic acid; CA -carbonic anhydrase; CHRNA2 -cholinergic receptor nicotinic alpha 2 subunit; CHRNA4 -cholinergic receptor nicotinic alpha 4 subunit; CHRNB2 -cholinergic receptor nicotinic beta 2 subunit; CNS -central nervous system; DBS -deep brain stimulation; ED 50 -median effective dose; GABA -γ-aminobutyric acid; i.p. -intraperitoneal; NMDA -N-methyl--D-aspartate; GABRG2 -gamma-aminobutyric acid type A receptor gamma 2 subunit; GAT1 -GABA transpoter-1; GEFS+ -generalized epilepsy with febrile seizures plus; MBD2 -methyl cytosine--phosphate-guanine binding domain 2; MES -maximal electroshock seizure; PI -protective index; SCN1A -sodium voltage-gated channel alpha 1 subunit; SCN2A -sodium voltage-gated channel alpha 2 subunit; SCN3A -sodium voltage-gated channel alpha 3 subunit; SCN1B -sodium voltage-gated channel beta 1 subunit; SCN2B -sodium voltage-gated channel beta 2 subunit; scPTZ -subcutaneous pentylenetetrazole; SSA -succinate semi-aldehyde; SV2 -synaptic vesicle protein 2; TD 50 -median toxic dose
